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Abstract  
 
In this study, prilling was evaluated as a technique for the development of multiparticulate 
dosage forms using the fatty acids stearic acid and behenic acid as potential matrix formers 
to control the release of metoprolol tartrate (MPT), a highly water soluble drug. The in vitro 
drug release was dependent on the drug load, type of fatty acid and pH of the dissolution 
medium. Higher drug loads resulted in faster release with behenic acid releasing drug over 
longer periods relative to stearic acid. The in vitro drug release was pH-dependent at low 
drug load with the release being slower at lower pH. Due to ionization of the fatty acid at pH 
7.4, drug release was susceptible to the ionic strength at this pH value. Solid state 
characterization indicated that the crystalline state of the fatty acids was not affected by 
thermal processing via prilling, while the crystallinity of MPT was decreased. During storage, 
the amorphous MPT fraction recrystallized in the entire matrix. Drug release from behenic 
acid matrices was increased during storage at 40 °C, however no polymorphism of behenic 
acid was detected. The bioavailability of MPT, after oral administration to dogs as prills 
containing 30 % and 40 % MPT using behenic acid as matrix former, was not significantly 
different from a commercial sustained release reference formulation, although the 40 % MPT 
prills showed a burst release.  
 
Keywords: Prilling, fatty acids, metoprolol tartrate, controlled release, multiparticulate 
dosage forms, stability 
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1. INTRODUCTION 
The need for alternative excipients that allow for continuously producing solid dispersions 
to improve the dissolution of poorly water soluble drugs or to create sustained release 
dosage forms has been reported by different authors [1-4]. The application of oral sustained 
release formulations has improved patient compliance due to a lower dosing frequency and a 
reduced incidence of adverse side effects [5]. Moreover, the production of sustained release 
multiparticulate dosage forms is advantageous since their transport in the gastro-intestinal 
tract is independent of gastric emptying and they exhibit a reduced risk of dose accumulation 
and local irritation when compared to single-unit dosage forms [6]. 
Lipid-based excipients such as triglycerides and fatty acids have been used for the 
development of solid dosage forms as matrices for controlled drug release [7-10], as taste-
masking agents [11], to enhance drug solubility [12-14] and for the manufacturing of floating 
dosage forms [15, 16]. Compared to polymers [17], triglycerides exhibit several advantages, 
including low cost, non-toxicity and biodegradability. Nevertheless, their physical instability 
during storage (reflected in changes in the melting enthalpy and melting range which modify 
drug release [10]), remains the main barrier to overcome when applying these excipients for 
drug formulation [7, 18].  
While lipid-based solid dosage forms have been processed using techniques such as 
solid lipid extrusion [19], extrusion/spheronisation [20], melt granulation [21], melt 
pelletization [7, 9] and spray-congealing [13], prilling has received limited attention in the 
pharmaceutical industry as a technique to efficiently incorporate drugs in a multiparticulate 
lipid-based solid dosage form. The prilling process consists of pumping a mixture of drug and 
lipid through calibrated nozzles, creating a liquid jet. By applying vibrational energy, the liquid 
jet breaks up into droplets which are then cooled by falling through a temperature-controlled 
prilling tower [22]. This technique offers the advantage of obtaining in a continuous fashion 
spherically shaped particles with a narrow particle size distribution. Having excellent flow 
properties, the particles can be easily filled into gelatin capsules [23], creating a 
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multiparticulate formulation. Additionally, no solvent is involved, resulting in a shorter and 
environmentally friendly pharmaceutical process. However, the major disadvantage of the 
prilling process is the need of a high prilling tower, linked to higher costs and difficulties in 
operation and maintenance [24]. 
The aim of this study was to evaluate the use of prilling for the manufacturing of 
multiparticulate dosage forms using fatty acids as potential matrix formers to control the 
release of highly water soluble drugs. For this purpose, stearic acid and behenic acid, C18 
and C22 fatty acids, respectively, were combined with metoprolol tartrate (MPT) as model 
drug and the in vitro performance was assessed. The solid state of the formulations, termed 
‘prills’ further on in this study, was characterized using modulated differential scanning 
calorimetry (MDSC), X-ray diffraction (XRD), Raman spectroscopy, Raman microscopic 
mapping and attenuated total reflection Fourier-transform (ATR FT-IR) spectroscopy. 
Furthermore, the physical stability of the prills during 6 months storage at 25 and 40 °C was 
monitored. Finally, the bioavailability of the different formulations was evaluated after oral 
administration to dogs and compared to a commercial sustained release formulation.  
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2. MATERIALS AND METHODS 
2.1 Materials 
Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain) was selected as a model 
drug. Behenic acid (Radiacid 0560) was purchased from Oleon (Ertvelde, Belgium) and had 
a C22 purity of 89 %. Stearic acid, with a C18 purity of 98.7 %, was purchased from 
Mosselman (Ghlin, Belgium). All other chemicals were of analytical grade. 
2.2 Methods 
2.2.1 Prilling 
Prilling was carried out with a custom-made prilling equipment developed by Peira 
(Turnhout, Belgium). After melting the fatty acid and heating the melt to 90 °C (stearic acid) 
or 100 °C (behenic acid), MPT was added to the melt under stirring. Droplet formation was 
started after complete dissolution of the drug in the molten matrix. By applying air pressure, 
the mixture was fed towards the thermostated nozzle (90 °C) equipped with a valve and a 
needle (inner diameter: 0.33 mm). To manufacture solid particles containing 10 % MPT and 
using behenic acid as matrix former, a drop time (i.e. period during which the valve is open) 
of 0.04 s and an air pressure of 0.5 bar were applied, whereas the drop time and air pressure 
were set at 0.07 s and 0.5 bar for the 20 % MPT and 30 % MPT formulation. When the drug 
load was increased to 40 %, a drop time of 0.07 s and a pressure of 1 bar were used. A drop 
time of 0.04 s and an air pressure of 0.5 bar were needed for all MPT/stearic acid 
combinations. Droplets formed at the needle end, were quench cooled in liquid nitrogen in 
order to obtain solid spherical particles. 
2.2.2 Particle size and shape 
The particle size and shape were determined using an image analysis system. 
Photomicrographs of the prills were taken with a digital camera (Camedia® C-3030 Zoom, 
Olympus, Tokyo, Japan), linked with a stereomicroscope system (SZX9 DF PL 1.5x, 
Olympus, Tokyo, Japan). A cold light source (Highlight 2100, Olympus, Germany) and a ring 
light guide (LG-R66, Olympus, Germany) were used to obtain top illumination of the prills 
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against a dark surface. The images were analyzed by an image analysis software 
(AnalySIS®, Soft Imaging System, Münster, Germany). At least 20 particles were analyzed 
from each batch. Each individual particle was characterized by the mean Feret diameter (FD) 
(average of 180 calliper measurements with an angle of rotation of 1°). An average value for 
all prills has been calculated as the mean particle size (mean FD). To evaluate sphericity, 
particles were characterized by the aspect ratio (AR) (ratio of the longest Feret diameter and 
its longest perpendicular diameter).  
2.2.3 In vitro drug release 
In vitro dissolution was performed using USP dissolution apparatus 1 (baskets). The 
equipment consisted of a VK 7010 dissolution system coupled with a VK 8000 automatic 
sampling station (Vankel, New Jersey, USA). An amount of prills corresponding to 30 mg 
MPT was inserted into the baskets. The basket rotational speed was set at 100 rpm and the 
temperature of the dissolution medium was maintained at 37 ± 0.5 °C. Samples of 5 ml were 
withdrawn after 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and analyzed spectrophotometrically at 
222 nm using a double beam spectrophotometer (UV-1650PC, Shimadzu, Antwerp, 
Belgium). MPT concentrations were calculated from a calibration curve between 0 and 33 
µg/ml. Demineralized water, 0.1N HCl (pH 1) and a phosphate buffer (USP, pH 7.4) were 
used as dissolution media. The influence of the ionic strength µ on MPT release was studied 
in diluted phosphate buffer with µ = 0.0089 (10-fold dilution), µ = 0.018 (5-fold dilution) and µ 
= 0.045 (2-fold dilution), phosphate buffer (µ = 0.089), phosphate buffer with increasing NaCl 
concentrations (µ = 0.14 and µ = 0.20), 0.1N HCl and 0.1N HCl with µ = 0.20. Each 
experiment was performed in triplicate. The similarity between dissolution profiles was 
evaluated using the similarity factor f2, according to Shah et al. (1998), and was calculated 
using the following equation (Eq. 1): 
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where Rt and Tr represent the cumulative drug release at each sample point of the reference 
and the test sample with n equal to the number of sample points. As f2 is sensitive to the 
number of sample points leading to bias, only one sample point exceeding a drug release of 
85 % was considered in the calculation. f2 values higher than 50 indicate similarity between 2 
dissolution profiles based on an average difference of less than 10 %, while f2 values below 
50 represent significant differences [25].  
2.2.4 Modulated differential scanning calorimetry 
The thermal behavior of the pure compounds (MPT, stearic acid and behenic acid), the 
physical mixtures and the corresponding formulations was evaluated using a differential 
scanning calorimeter Q2000 (TA Instruments, Zellik, Belgium) equipped with a refrigerated 
cooling system. The DSC was calibrated for temperature and enthalpy using an indium 
standard. Tzero calibration was performed in 2 steps; baseline calibration (without samples 
or pans) and sapphire calibration (using large sapphire disks on both the sample and 
reference positions). Small sapphire disks, placed in a Tzero pan, were used for the heat 
capacity (MDSC) calibration. Samples (± 5 mg) were run in Tzero pans (TA Instruments, 
Zellik, Belgium) with an underlying heating rate of 2 °C/min. The modulation period and 
amplitude were set at 60 s and 0.318 °C, respectively (heat-iso method). Dry nitrogen was 
used as a purge gas through the DSC cell at a flow rate of 50 ml/min. MDSC data were 
analyzed using the Universal Analysis software (TA Instruments). Melting enthalpies were 
determined in the total heat flow signal. Melting temperatures were reported as onset 
temperatures. 
2.2.5 X-ray diffraction 
Crystallinity was analyzed using X-ray diffraction on the pure compounds, the physical 
mixtures and the corresponding formulations. X-ray diffraction was performed with a D5000 
Cu Kα diffractor (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) with a voltage of 40 mV in the 
angular range of 10° < 2θ < 60° using a step scan mode (step size = 0.02°, counting time = 
1s/step). 
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2.2.6 FT-IR analysis 
 Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 
performed on the pure substances, physical mixtures and prills to identify the interactions 
that were formed between MPT and the fatty acids during prilling. Spectra were recorded 
using a Bruker Vertex 70 FT-IR spectrometer equipped with a Hyperion FT-IR microscope 
and MCT detector. A Ge ATR crystal was pressed against the prills in order to obtain the 
ATR FT-IR spectra (4 cm-1 resolution, 50 scans). 
2.2.7 Raman spectroscopy 
Raman spectra were collected with a Raman Rxn1 spectrometer (Kaiser Optical 
Systems, Ann Arbor, MI, USA), equipped with an air-cooled CCD detector. The laser 
wavelength was the 785 nm line from a 785 nm Invictus NIR diode laser. All spectra were 
recorded over the 0 – 1800 cm-1 range with a resolution of 4 cm-1 and an exposure time of 5 
s, using a laser power of 400 mW. Data collection and data transfer were automated using 
the HoloGRAMSTM data collection software, the HoloREACTTM reaction analysis and profiling 
software and the Matlab software (version 7.1, The MathWorks Inc., Natick, MA). Data 
analysis was performed using SIMCA P+ (Version 12.0.1.0, Umetrics, Umeå, Sweden). All 
spectra were SNV-preprocessed. Raman spectroscopy was performed on the pure 
compounds, the physical mixtures and the corresponding formulations. 
The solid state distribution of MPT in the prills was evaluated by Raman microscopic 
mapping using a Raman Rxn1 Microprobe. Cross sections of prills were scanned by a 10 x 
long working distance objective lens (spot size 50 µm) in area mapping mode using an 
exposure time of 4 s and a step size of 50 µm in both the x and y directions (= 234 spectra 
per mapping). The resulting images provide information about the distribution of the solid 
state of MPT in the prills.  
2.2.8 Storage 
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The formulation containing 30 % MPT and 70 % behenic acid was selected for a stability 
study. Immediately after prilling, the formulation was filled in hermetically sealed bags under 
controlled circumstances (35% RH) and stored at 25 °C and 40 °C. To investigate the 
influence of storage on solid state and drug release, the prills were studied immediately after 
manufacturing, after 1 week, 1 month, 3 months and 6 months storage. The solid state was 
analyzed using MDSC, XRD, Raman spectroscopy and Raman microscopic mapping. 
2.2.9 In vivo evaluation 
All procedures were performed in accordance with the guidelines and after approval by 
the Ethics Committee of the Institute for Agricultural and Fisheries Research (ILVO) 
(Merelbeke, Belgium). To study the influence of MPT concentration, the following 
formulations were administrated to 6 dogs:  
Formulation 1 (F1): prills containing 30 % MPT and 70 % behenic acid          
Formulation 2 (F2): prills containing 40 % MPT and 60 % behenic acid  
Formulation 3 (F3): Slow-Lopresor® 200 Divitabs® (Sankyo, Louvain-la-Neuve, Belgium), a 
commercial sustained release formulation consisting of matrix tablets containing 200 mg 
MPT. 
The test formulations F1 and F2 were filled in hard-gelatin capsules, corresponding to 
200 mg MPT. Slow-Lopresor® 200 Divitabs® (1 tablet) was used as a reference formulation 
(F3). All formulations were administrated to 6 male mixed-breed dogs (23 - 41.5 kg) in a 
cross-over study with a wash-out period of at least 8 days. The dogs were fasted 12 h prior 
to the administration and 12 h after administration, although water was available ad libitum. 
Before the administration, an intravenous cannula was placed in the lateral saphenous and a 
blank blood sample was collected. The formulations were administrated with 20 ml water and 
blood samples were collected in dry heparinized tubes at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 
12 h after administration. The obtained blood samples were centrifugated at 1500 g during 5 
min.  
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2.2.9.1 Metoprolol tartrate assay 
A validated HPLC method with fluorescence detection was used for the determination of 
MPT in dog plasma. Plasma samples (300 µl) were mixed with 20 µl of a 2.75 µg/ml aqueous 
bisoprolol hemifumarate (internal standard, IS) solution and 320 µl of a 4 % (v/v) aqueous 
phosphoric acid solution. The mixtures were vortexed during 30 s. Drug and internal 
standard were extracted using solid phase extraction (SPE) cartridges (Oasis® MCX 1 cc (30 
mg), Waters, Brussels, Belgium) and a 10-port vacuum extraction manifold. After 
conditioning the SPE columns with 1 ml methanol and 1 ml water, the plasma samples were 
transferred to the columns. The columns were rinsed with 1 ml of a 2 % (v/v) aqueous formic 
acid solution, followed by 1 ml methanol. 1 ml of a 5 % (v/v) solution of ammonium hydroxide 
in methanol was used to elute MPT and IS. Samples were evaporated to dryness under a N2-
flow and reconstituted in 150 µl distilled water. 20 µl was injected into the HPLC system. 
MPT plasma concentrations were calculated from a calibration curve, determined by adding 
20 µl of a MPT standard (0.375, 0.5625, 0.75, 1.5, 2.25, 3.75 and 5.25 µg/ml), 20 µl of the IS 
solution and 320 µl of an aqueous phosphoric acid solution (4% (v/v)) to 280 µl of blank 
plasma. The mixtures were then treated as described previously. The method validation 
indicated a linear relationship between MPT plasma concentration and response (range: 0 – 
353.5 ng/ml; R2 = 0.999 ± 0.001 (n = 8)). The limit of detection and limit of quantification were 
10.1 and 30.6 ng/ml, respectively. MPT showed a retention time of 14 min, while the IS 
eluted after 18 min.  
The HPLC system consisted of an isocratic solvent pump (L-7100, Merck, Hitachi 
LaChrom, Tokyo, Japan), an automatic autosampler (L-2200, Merck, Elite LaChrom, Tokyo, 
Japan), a guard column (LiChroCart® 4-4, LiChrospher® 100 CN (5 µm), Merck, Darmstadt, 
Germany) followed by a reversed phase CN column (LiChroCart® 250-4, LiChrospher® 100 
CN (5 µm), Merck, Darmstadt, Germany) and a variable wavelength fluorescence detector 
(L-7480, Merck, Hitachi LaChrom, Tokyo, Japan). Peak integration was performed using the 
software package D-7000 HSM Chromatography Data Station (Hitachi Instruments, San 
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Jose, CA, USA). The mobile phase consisted of a phosphate buffer solution (2M sodium 
phosphate monobasic dihydrate), acetonitrile and water (0.5/3.5/96; v/v/v) adjusted to pH 3 
with phosphoric acid. The pump flow was set at 1.1 ml/min and the excitation and emission 
wavelength were 275 nm and 300 nm, respectively.  
2.2.9.2 Data analysis 
The peak plasma concentration (Cmax), the extent of absorption (AUC0-12h) and the time 
needed to reach the highest plasma concentration (tmax) were determined. The controlled 
release characteristics of the formulations were evaluated by means of the HVDt50%Cmax (half-
value duration) defined by the period during which the plasma concentration exceeds 50 % 
of the Cmax [26, 27]. The effect of the formulation on the bioavailability was statistically 
evaluated by repeated-measures ANOVA (univariate analysis) using SPSS 17 (SPSS, 
Chicago, USA). To compare the effects of the different treatments on the pharmaco-kinetic 
parameters, a multiple comparison among pairs of means was performed using a Bonferroni 
post-hoc test with p < 0.05 as significance level. 
  
12 
 
3. RESULTS AND DISCUSSION 
3.1 In vitro drug release 
Prilling was performed using a process temperature ranging between 90 °C and 100 °C. 
Thermogravimetric analysis (TGA), performed on MPT, stearic acid and behenic acid, 
indicated thermal stability of these compounds at the process temperature (data not shown). 
In a first step, the fatty acids were molten and MPT was added to the melt. Next, droplet 
formation was started after complete dissolution of the drug in the molten carrier. Process 
parameters were chosen in order to obtain a fast droplet formation at the needle-end and to 
limit the residence time of the drug/lipid mixture in the reservoir. Drug load influenced the 
processability as a higher air pressure was required to process mixtures with a higher melt 
viscosity. The mean particle size and shape of the prills, determined by measuring the mean 
Feret diameter and aspect ratio (AR), are shown in Table 1 for prills containing 10 %, 20 %, 
30 % and 40 % MPT in a behenic acid matrix and for prills containing 30 % MPT in a stearic 
acid matrix. Only minor variations in particle size were noticed for the 10 %, 20 % and 30 % 
MPT formulations, however the 40 % MPT prills had a remarkable smaller particle size 
possibly attributed to the higher air pressure needed to process this mixture. As all aspect 
ratio’s approached the ideal sphericity value of 1, these data indicated that prilling resulted in 
spherically shaped particles with a narrow particle size distribution. All particles exhibited a 
smooth surface.  
The influence on drug release using behenic acid or stearic acid as matrix formers, in 
combination with 30 % MPT, is illustrated in Fig. 1A. Drug release in water was found to be 
faster using stearic acid as matrix former since 94 % of the total drug load was released after 
4 h, while only 62 % was released when MPT was incorporated in a behenic acid matrix. The 
slower drug release using behenic acid could be attributed to its longer fatty acid chain 
relative to stearic acid. In a study performed by Desai et al. (2010), a similar influence of 
chain length on drug release was reported [28]. Since behenic acid released MPT over 
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longer periods, only the combination of MPT and behenic acid is discussed further on in this 
study. 
Fig. 1B represents the dissolution profiles in water for prills containing 10 %, 20 %, 30 % 
and 40 % MPT in a behenic acid matrix. At low drug load (10 %), only 38 % of the MPT was 
released after 24 h. The release rate was enhanced by increasing the drug load, although 
only minor differences between prills containing 20 % MPT and 30 % MPT were observed, 
reflected by a similarity factor of 53. The influence of pH on drug release of the 10 % and 30 
% MPT formulations was evaluated in two dissolution media: 0.1N HCl (pH 1) and phosphate 
buffer (USP, pH 7.4) to mimic the pH conditions in the stomach and the small intestine, 
respectively. Drug release was pH-dependent at low drug concentration (10 %) (Fig. 1C). At 
pH 7.4, 91 % of MPT was released after 20 h compared to 62 % after 24 h at pH 1. This 
effect was attributed to (partial) ionization of the carboxyl group of behenic acid at higher pH, 
resulting in a less hydrophobic matrix. When the drug load was increased to 30 %, the 
differences between the 2 dissolution media were smaller and MPT was released faster: at 
pH 1, 93 % of MPT was released after 12 h (data not shown). Due to the higher drug load, an 
extended channel system was possibly generated in the prills during immersion, 
consequently the matrix effect of behenic acid was less pronounced. Since the morphology 
of the prills was unchanged after dissolution, MPT release from the lipid matrices was 
diffusion-controlled. 
Next, the influence of the ionic strength of the dissolution medium on the drug release 
was investigated. Fig. 1D demonstrates that at pH 7.4, for prills containing 30 % MPT and 70 
% behenic acid, the slowest drug release was obtained in the dissolution medium with the 
highest ionic strength. Only 62 % MPT was released after 8 h in a medium of µ = 0.20, 
whereas 88 % and 97 % were released after 8 h in the media of µ = 0.089 and µ = 0.018, 
respectively. Further dilution (µ = 0.009) of the medium had no influence anymore on the 
release profiles. Increasing the ionic strength at pH 1 did not alter the release profile in this 
medium (data not shown). At higher pH, the ionized carboxyl group of behenic acid interacts 
14 
 
with positively charged ions from the dissolution medium, resulting in slower drug release. A 
similar influence of the ionic strength on drug release was noticed for the 10 % MPT 
formulation (data not shown). Johnson et al. (1992) reported that the electrolyte composition 
of the gastrointestinal fluids ranged from 0.010 to 0.166 and hence, the drug release from 
behenic acid matrices will likely be affected during the transit in the gastrointestinal tract [29]. 
The susceptibility of lipid formulations to ionic strength was also reported by Chang et al. 
(1997). The release of propranolol hydrochloride from monoglyceride matrices showed only a 
minor susceptibility to the ionic strength at pH 7.4 as monoglycerides are non-ionic 
amphiphilic molecules [30].  
3.2 Thermal behavior and crystallinity 
Fig. 2 shows the MDSC thermograms for MPT, stearic acid, behenic acid, the 30/70 
MPT/fatty acid physical mixtures and the corresponding formulations. Metoprolol tartrate 
showed an onset melting temperature at 120.7 °C, while stearic acid and behenic acid 
started melting at 68.2 °C and 74.7 °C, respectively, indicating the crystalline state of these 
compounds. Even-numbered saturated fatty acids can crystallize in at least four polymorphs, 
named A, B, C and E. As form C is thermodynamically stable at high temperature, all other 
polymorphs irreversibly transform into form C upon heating [31]. However, as no solid-solid 
transformations were detected prior to the melting endotherms of stearic and behenic acid 
(i.e. 68 and 75 °C, corresponding to the melting point of the C polymorph), it indicates that 
only the polymorph C was present in the formulations [32]. These findings were in agreement 
with Kobayashi (1988), who stated that only the thermostable C-form could be formed from a 
melt [31]. In contrast, Corvis et al. (2011) reported recrystallization of stearic acid in the E-
form from a ibuprofen/stearic acid melt. However, upon heating, this polymorph converted to 
the thermostable C-form at about 45 °C [32]. Thermal analysis of the physical mixtures and 
the formulations only revealed a melting endotherm of the fatty acids due to dissolution of the 
MPT crystals in molten stearic acid or behenic acid. Addition of MPT lowered the melting 
temperature of the fatty acids with a few degrees. A glass transition temperature of MPT 
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could not be detected in the reversed heat flow signal of the formulations. In the physical 
mixtures and the formulations, the melting enthalpy of fatty acids was higher than expected, 
suggesting that the excess of energy was needed to dissolve the MPT crystals.  
The solid state was also characterized using XRD and Raman spectroscopy. The X-ray 
diffraction patterns of the pure compounds, the 30/70 MPT/behenic acid physical mixture and 
the corresponding formulation are shown in Fig. 3. MPT showed representative peaks for 2θ 
at 10.7°, 16.0°, 19.6° and 23.3°. The highly crystalline state of behenic acid was indicated by 
sharp diffraction peaks at 21.7° and 24.3°. As these peaks also showed up in the formulation, 
it could be concluded that the crystallinity of the fatty acid was not affected by thermal 
processing via prilling. The X-ray diffraction pattern for the formulation also revealed 
diffraction peaks of MPT, demonstrating that the crystalline state of MPT was at least 
partially maintained in the prills. These results were in agreement with the Raman spectra 
shown in Fig. 4. However, the representative Raman peaks for MPT in the region 800 – 875 
cm-1, representing the out-of-plane O-H vibration of the carbonyl group [33], had broadened 
in the formulation (Fig. 4A) in comparison with the physical mixture. In the 920 – 980 cm-1 
region, depicting the O-H deformation [33], MPT bands in the formulation had almost 
disappeared, indicating a decrease in crystallinity and the presence of amorphous MPT. 
Moreover, the MPT band at 1210 cm-1, corresponding to the C-N stretching vibration [33], 
was shifted to a lower wavenumber (Fig. 4B), revealing interactions between the drug and 
the fatty acid. During processing at higher temperature, MPT dissolved in the molten behenic 
acid phase and the interactions between drug and carrier were partially retained after cooling 
as indicated by changes in the Raman spectrum. Based on the crystalline nature of the fatty 
acid matrix, it is unlikely that the MPT fraction interacting with the carrier is molecularly 
dispersed throughout the lipid carrier, hence it is suggested that an amorphous MPT fraction 
is distributed as separate phases throughout the entire matrix. The combination of MPT with 
stearic acid via prilling resulted in similar changing Raman bands of MPT (data not shown). 
ATR FT-IR spectroscopy (Fig. 5) confirmed that the prilling process generated hydrogen 
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bonds and Van der Waals interactions between MPT and the fatty acids and that the 
complete MPT molecule was involved in these interactions. Fig. 5 illustrates that the ratios of 
the vibration peaks of MPT and fatty acids in the prills were significantly different from the 
physical mixture with the characteristic vibration peaks of MPT (1584 cm-1 and 1512 cm-1, 
1249 cm-1, 1109 cm-1 and 821 cm-1 for the C=C stretch vibrations of the aromatic ring,  in-
plane bending of the hydroxyl groups, C-OH stretching of the hydroxyl groups and  out-of-
plane bendings of the aromatic C-H bonds, respectively) appearing less intense in the prills. 
Since no additional carboxyl vibrations appeared in the prills, electrostatic interactions 
between MPT and the fatty acids could be excluded. These observations were confirmed by 
solid state 13C – NMR (data shown in supporting information). 
3.3 Physical stability 
Stability issues when using lipid excipients have been reported by different authors [7, 10, 
18]. Influences of storage parameters on drug release were observed by Hamdani et al. 
(2002). The prolonged release of phenylephrine hydrochloride from fatty binder mixtures 
(Precirol® and Compritol®) was significantly affected by storage after 6 weeks at 40 °C and 
75 % relative humidity (RH) [7]. In a study performed by San Vicente et al. (2000), 
salbutamol hydrochloride release was altered after storage for 1 year at room temperature, 
depending on the type of Gelucire used [18].  
To investigate the physical stability, the prills containing 30 % MPT and 70 % behenic 
acid were stored, immediately after manufacturing, in hermetically sealed bags at 25 °C and 
40 °C during 6 months. The influence of storage on drug release is shown in Fig. 6. Drug 
release profiles remained similar during storage at 25 °C as indicated by the f2 values, 
ranging between 73 and 85, whereas the release rate increased during storage at 40 °C. 
After one week of storage at 40 °C, 73 % MPT was released after 4 h, compared to 62 % 
immediately after manufacturing. The drug release after 4h was increased to 80 % after one 
month of storage. Drug release profiles obtained after one month, 3 months and 6 months of 
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storage were not significantly different (f2 > 50), but differed significantly from the freshly 
prepared formulation (f2 < 50).  
X-ray patterns of the 30 % MPT formulation stored during 6 months at 25 °C and 40 °C 
are compared with the X-ray pattern of the formulation immediately after processing in Fig. 3. 
MPT diffraction peaks show similarity between the 3 formulations. The sharp diffraction 
peaks of behenic acid at 21.7° and 24.3° are unchanged during storage at both conditions, 
indicating the stability of the crystalline structure. These results were confirmed by MDSC 
measurements (Table 2). Only small fluctuations in onset melting temperature and peak 
melting temperature (Tm) were detected during storage at 25 °C and 40 °C. Moreover, the 
melting enthalpy of behenic acid showed a similar trend at both storage conditions. 
Differences in MPT solid state during storage were observed with Raman spectroscopy (Fig. 
7). At both storage conditions, Raman absorption bands for MPT (800 – 875 cm-1) had 
sharpened after 1 week compared to the formulation immediately after prilling and MPT 
bands that were absent in the 920 – 980 cm-1 region due to the prilling process, became 
visible again. The MPT band at 1206 cm-1 was shifted back to 1210 cm-1 after 1 week. This 
indicated a transition of MPT from its amorphous state to its crystalline state during the first 
week of storage. The Raman spectra collected after 1 month, 3 months and 6 months 
storage were not significantly different. The influences of storage on Raman bands of 
behenic acid are shown in Fig. 7G and 7H, respectively. No changes or shifts were detected 
at 25 °C, neither at 40 °C, indicating no polymorphism of behenic acid during both production 
and storage of the prills.  
To evaluate the distribution of the solid state during storage, Raman microscopic 
mapping was performed and compared with the formulation immediately after processing. 
The peak width of the Raman band of MPT in the 810 - 830 cm-1 region was monitored to 
map the solid state of MPT in the matrix since there was no interference of behenic acid in 
this region. Fig. 8 shows the distribution of MPT in the inner and outer layers immediately 
after prilling and after 2 days storage, a red color corresponds to a broad peak width, while a 
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blue color corresponds to a smaller peak width. The MPT band in the 810 – 830 cm-1 region 
showed a broad peak width in the inner (Fig. 8A) and outer layers (Fig. 8B) confirming the 
initial presence of amorphous MPT which can be attributed to the fast cooling rate applied to 
the droplets. Raman microscopic mapping after 2 days of storage at 25 °C and 40 °C (Fig. 
8C - 8F) indicated that the amorphous MPT fraction was recrystallized in the entire matrix. 
Although difficult to conclude for the inner layers in the stored prills (Fig. 8D and 8F), the 
mean Raman spectra collected in this region showed increased MPT crystallinity. In 
comparison with the freshly prepared formulation, the Raman peaks in the 810 - 875 cm-1 
had sharpened and the peak at 1206 cm-1 was shifted to 1210 cm-1. Raman microscopic 
mapping performed after 6 months storage did not show significant differences with the 
images obtained after 2 days. MPT crystals remained homogenously distributed in the fatty 
acid matrix. 
Although the faster dissolution rate of MPT during the first month of storage at 40 °C 
could not be clarified by means of solid state characterization, a higher mobilization of the 
fatty acid chains at higher storage temperature might be a contributing factor, thereby 
inhibiting crystallization of MPT or yielding smaller drug crystals, thus affecting the release 
rate.  
3.4 In vivo evaluation 
To study the MPT bioavailability, the prills containing 30 % MPT (Formulation 1, F1) and 
40 % MPT (Formulation 2, F2) in a behenic acid matrix, were selected for in vivo evaluation 
in dogs. The bioavailability was compared with a commercially available controlled release 
reference formulation (Formulation 3, F3): Slow-Lopresor® 200 mg Divitabs®. The in vitro 
drug release from the reference, with a complete drug release after 12 h, was faster 
compared to F1 and slower compared to F2 (data not shown). The mean plasma 
concentration-time profiles (n = 6) after oral administration of F1, F2 and F3 are illustrated in 
Fig. 9, while the mean pharmacokinetic parameters (AUC, Cmax, tmax and HVDt50%Cmax) are 
reported in Table 3. The fast in vitro drug release from F2 was reflected in the in vivo study 
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since this formulation showed a burst release with a mean Cmax of 6.75 (µg/ml)*kg obtained 
after 1.67 h compared with a Cmax of 4.20 and 3.44 (µg/ml)*kg obtained after 2.33 h and 3.83 
h after administration of F1 and F3, respectively. Moreover, F2 was characterized by a lower 
HVDt50%Cmax, illustrating less controlled release characteristics. Prills containing 30 % MPT 
(F1) showed a similar plasma concentration-time profile compared with the reference (F3). 
Statistical analysis of the pharmacokinetic parameters (AUC, Cmax, tmax and HVDt50%Cmax) 
revealed no significant differences between the 3 formulations (p > 0.05). Remnants of prills, 
which still contained 4.39 % MPT, were found in the faeces of the dogs after administration 
of F1. Although the prills containing 40 % MPT (F2) were intact after in vitro dissolution, no 
prills were recovered from the faeces after oral administration of these multiparticulates to 
dogs, indicating that the composition of gastro-intestinal fluid and motility play an important 
role in the disintegration of these solid lipid dosage forms.  
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4. CONCLUSION 
In this study we have demonstrated that prilling is a promising technique for the 
production of multiparticulate dosage forms. Using the fatty acids stearic acid and behenic 
acid, sustained release of the hydrophilic drug MPT could be achieved. In vitro drug release 
was dependent on the drug load, type of fatty acid, pH and ionic strength of the dissolution 
medium. Solid state characterization indicated that the crystalline state of the fatty acids was 
not affected by thermal processing via prilling, while the crystallinity of MPT was decreased. 
During storage, the amorphous MPT fraction recrystallized in the entire matrix but no 
polymorphism of behenic acid was detected. The in vivo bioavailability of MPT, after oral 
administration of the test formulations to dogs, did not significantly differ from a commercial 
sustained release reference formulation. 
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Figures 
Fig. 1. Drug release in function of (A) fatty acid: 30 % MPT in combination with stearic acid 
(●) and behenic acid (▲); (B) drug load: 10 % (●), 20 % (■), 30 % (▲) and 40 % MPT (▼); 
(C) pH of the dissolution medium: 10 % MPT in pH 1 (●) and pH 7.4 (■); (D) ionic strength of 
the dissolution medium: µ = 0.009 (●), 0.018 (■), 0.044 (▲), 0.089 (▼), 0.1445 (♦) and 0.20 
(○). 
Fig. 2. MDSC thermograms of MPT (A), stearic acid (B), behenic acid (C), physical mixture 
of 30/70 MPT/stearic acid (D), physical mixture of 30/70 MPT/behenic acid (E), prills 
containing 30 % MPT and 70 % stearic acid (F) and prills containing 30 % MPT and 70 % 
behenic acid (G). 
Fig. 3. X-ray diffraction patterns of MPT (A), behenic acid (B), physical mixture of 30/70 
MPT/behenic acid (C), prills containing 30 % MPT and 70 % behenic acid immediately after 
manufacturing (D), after 6 months storage at 25 °C (E), after 6 months storage at 40 °C (F). 
Fig. 4. Raman spectra of MPT (green), behenic acid (blue), 30/70 MPT/behenic acid physical 
mixture (black) and prills containing 30 % MPT and 70 % behenic acid (red).  
Fig. 5. ATR FT-IR spectra of MPT (A), prills containing 30 % MPT and 70 % behenic acid 
(B), 30/70 MPT/behenic acid physical mixture (C) and behenic acid (D). 
Fig. 6. Influence of storage at 25 °C (A) and 40 °C (B) on drug release. Mean dissolution 
profiles (± S.D.) of prills containing 30 % MPT and 70 % behenic acid immediately after 
manufacturing (●), after 1 week (■), 1 month (▲) and 6 months (♦) of storage. 
Fig. 7. Raman bands for MPT (A – F) and behenic acid (G – H) in prills containing 30 % MPT 
and 70 % behenic acid immediately after manufacturing (black) and after 1 week (red), 1 
month (green), 3 months (blue) and 6 months (orange) storage at 25 °C (A, C, E and G) and 
at 40 °C (B, D, F and H).   
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Fig. 8. Solid state mapping of MPT in prills containing 30 % MPT and 70 % behenic acid 
immediately after prilling (A-B), after 2 days storage at 25 °C (C-D) and 40 °C (E-F). Figures 
A, C and E represent the  outer layers, whereas the inner layers are represented in figures B, 
D and F. A red color corresponds to a broad peak width, blue corresponds to a smaller peak 
width.  
Fig. 9. Mean plasma-concentration time profiles (± S.D.) after oral administration of 200 mg 
metoprolol tartrate to dogs (n = 6) as prills containing 30 % MPT and 70 % behenic acid (●), 
as prills containing 40 % MPT and 60 % behenic acid (■), and as Slow-Lopresor® 200 
Divitabs®(▲). 
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Tables 
Table 1. Mean particle size (± S.D.) and aspect ratio (± S.D.) for prills containing different 
amounts of MPT in combination with stearic acid or behenic acid.  
Table 2. Thermal behavior of the prills during 6 months storage at 25 °C and 40 °C. The melt 
onset, peak melting temperature (Tm) and the melting enthalpy of the prills immediately after 
manufacturing were 69.8 ± 0.5 °C; 73.7 ± 0.1 °C and 144.8 ± 4.2 J/g, respectively.  
Table 3. Mean pharmacokinetic parameters (± S.D.) after oral administration of 200 mg 
metoprolol tartrate to dogs (n = 6) as prills containing 30 % MPT and 70 % behenic acid (F1), 
as prills containing 40 % MPT and 60 % behenic acid (F2) and as Slow-Lopresor® 200 mg 
Divitabs® (F3). 
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Fig. 1. Drug release in function of (A) fatty acid: 30 % MPT in combination with stearic acid 
(●) and behenic acid (▲); (B) drug load: 10 % (●), 20 % (■), 30 % (▲) and 40 % MPT (▼); 
(C) pH of the dissolution medium: 10 % MPT in pH 1 (●) and pH 7.4 (■); (D) ionic strength of 
the dissolution medium: µ = 0.009 (●), 0.018 (■), 0.044 (▲), 0.089 (▼), 0.1445 (♦) and 0.20 
(○). 
 
  
 Fig. 2. 
of 30/7
containi
behenic
 
 
 
 
 
 
 
 
MDSC ther
0 MPT/ste
ng 30 % M
 acid (G). 
mograms o
aric acid (
PT and 70
 
f MPT (A),
D), physic
 % stearic 
 stearic ac
al mixture 
acid (F) an
id (B), behe
of 30/70 
d prills co
nic acid (C
MPT/behen
ntaining 30 
), physical
ic acid (E
% MPT an
30 
 mixture 
), prills 
d 70 % 
 
31 
 
Fig. 3. X-ray diffraction patterns of MPT (A), behenic acid (B), physical mixture of 30/70 
MPT/behenic acid (C), prills containing 30 % MPT and 70 % behenic acid immediately after 
manufacturing (D), after 6 months storage at 25 °C (E), after 6 months storage at 40 °C (F). 
 
  
32 
 
Fig. 4. Raman spectra of MPT (green), behenic acid (blue), 30/70 MPT/behenic acid physical 
mixture (black) and prills containing 30 % MPT and 70 % behenic acid (red).  
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Fig. 5. ATR FT-IR spectra of MPT (A), prills containing 30 % MPT and 70 % behenic acid 
(B), 30/70 MPT/behenic acid physical mixture (C) and behenic acid (D). 
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Fig. 6. Influence of storage at 25 °C (A) and 40 °C (B) on drug release. Mean dissolution 
profiles (± S.D.) of prills containing 30 % MPT and 70 % behenic acid immediately after 
manufacturing (●), after 1 week (■), 1 month (▲) and 6 months (♦) of storage. 
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Fig. 7. Raman bands for MPT (A – F) and behenic acid (G – H) in prills containing 30 % MPT 
and 70 % behenic acid immediately after manufacturing (black) and after 1 week (red), 1 
month (green), 3 months (blue) and 6 months (orange) storage at 25 °C (A, C, E and G) and 
at 40 °C (B, D, F and H).   
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Fig. 8. Solid state mapping of MPT in prills containing 30 % MPT and 70 % behenic acid 
immediately after prilling (A-B), after 2 days storage at 25 °C (C-D) and 40 °C (E-F). Figures 
A, C and E represent the  outer layers, whereas the inner layers are represented in figures B, 
D and F. A red color corresponds to a broad peak width, blue corresponds to a smaller peak 
width.  
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Fig. 9. Mean plasma-concentration time profiles (± S.D.) after oral administration of 200 mg 
metoprolol tartrate to dogs (n = 6) as prills containing 30 % MPT and 70 % behenic acid (●), 
as prills containing 40 % MPT and 60 % behenic acid (■), and as Slow-Lopresor® 200 
Divitabs® (▲). 
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Table 1. Mean particle size (± S.D.) and aspect ratio (± S.D.) for prills containing different 
amounts of MPT in combination with stearic acid or behenic acid.  
% MPT 
% 
Behenic 
Acid 
% Stearic 
Acid 
Mean FD 
(mm) AR 
10 90 - 2.35 ± 0.07 1.07 ± 0.03 
20 80 - 2.36 ± 0.05 1.07 ± 0.04 
30 70 - 2.37 ± 0.06 1.09 ± 0.05 
40 60 - 1.83 ± 0.03 1.05 ± 0.02 
30 - 70 2.35 ± 0.05 1.08 ± 0.04 
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Table 2. Thermal behavior of the prills during 6 months storage at 25 °C and 40 °C. The melt 
onset, peak melting temperature (Tm) and the melting enthalpy of the prills immediately after 
manufacturing were 69.8 ± 0.5 °C; 73.7 ± 0.1 °C and 144.8 ± 4.2 J/g, respectively.  
 Melt Onset Temp. (°C) Tm (°C) Melting enthalpy (J/g) 
 25 °C 40 °C 25 °C 40 °C 25 °C 40 °C 
1 Week 70.4 ± 0.3 70.5 ± 0.1 73.6 ± 0.2 73.8 ± 0.1 154.8 ± 5.8 161.7 ± 2.2
1 Month 70.4 ± 0.2 70.8 ± 0.2 73.7 ± 0.2 73.9 ± 0.1 145.7 ± 3.9 153.0 ± 3.4
3 Months 70.7 ± 0.2 70.9 ± 0.2 74.1 ± 0.1 74.1 ± 0.1 157.2 ± 1.1 157.4 ± 2.3
6 Months 70.5 ± 0.1 70.8 ± 0.1 73.7 ± 0.1 74.0 ± 0.1 166.3 ± 1.9 164.9 ± 3.4
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Table 3. Mean pharmacokinetic parameters (± S.D.) after oral administration of 200 mg 
metoprolol tartrate to dogs (n = 6) as prills containing 30 % MPT and 70 % behenic acid (F1), 
as prills containing 40 % MPT and 60 % behenic acid (F2) and as Slow-Lopresor® 200 mg 
Divitabs® (F3). 
 
 
 
Cmax 
((µg/ml)*kg tmax (h) 
AUC 
((µg/ml)*kg*h) HVDt50%Cmax (h) 
F1 4,20 ± 1,82 2,33 ± 1,03 21,25 ± 10,96 4,29 ± 1,23 
F2 6,75 ± 3,79 1,67 ± 0,52 25,01 ± 11,41 3,37 ± 0,94 
F3 3,44 ± 1,52 3,83 ± 2,23 22,18 ± 12,16 5,98 ± 2,88 
 
